Elite in Hypertrichosis-Acromegaloid Facial Appearance Syndrome

Dr. Mark E. Molitch

Endocrinology
680 N Lake Shore Dr, Suite 1000, 
Chicago, IL 
Elite in Hypertrichosis-Acromegaloid Facial Appearance Syndrome
680 N Lake Shore Dr, Suite 1000, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Molitch is an Endocrinologist in Chicago, Illinois. Dr. Molitch is rated as an Elite provider by MediFind in the treatment of Hypertrichosis-Acromegaloid Facial Appearance Syndrome. His top areas of expertise are Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaly, Hormone Replacement Therapy (HRT), and Parathyroidectomy.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 15 articles in the study of Hypertrichosis-Acromegaloid Facial Appearance Syndrome.

Specialties
Endocrinology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

680 N Lake Shore Dr, Suite 1000, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Other, Drug
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

162 Total Publications

Debate: Surgery as Initial Therapy for Microprolactinoma.
Debate: Surgery as Initial Therapy for Microprolactinoma.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 06, 2025
Similar Doctors
Wenyu Huang
Experienced in Hypertrichosis-Acromegaloid Facial Appearance Syndrome
Dr. Wenyu Huang
Endocrinology
Experienced in Hypertrichosis-Acromegaloid Facial Appearance Syndrome
Dr. Wenyu Huang
Endocrinology

Northwestern Medical Faculty Foundation

350 S Waukegan Rd, 
Deerfield, IL 
 (20.6 miles away)
312-926-6146
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wenyu Huang is an Endocrinologist in Deerfield, Illinois. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Hypertrichosis-Acromegaloid Facial Appearance Syndrome. His top areas of expertise are Pituitary Tumor, Glucocorticoid Resistance, Familial Glucocorticoid Deficiency, and Hypoaldosteronism.

Experienced in Hypertrichosis-Acromegaloid Facial Appearance Syndrome
Dr. Mary P. Gillam
Endocrinology
Experienced in Hypertrichosis-Acromegaloid Facial Appearance Syndrome
Dr. Mary P. Gillam
Endocrinology
680 N Lake Shore Dr, Suite 1000, 
Chicago, IL 
 (0.1 miles away)
312-695-9797
Languages Spoken:
English
See accepted insurances

Mary Gillam is an Endocrinologist in Chicago, Illinois. Dr. Gillam is rated as an Experienced provider by MediFind in the treatment of Hypertrichosis-Acromegaloid Facial Appearance Syndrome. Her top areas of expertise are Hypothalamic Tumor, Pituitary Tumor, Acromegaloid Facial Appearance Syndrome, and Hypertrichosis-Acromegaloid Facial Appearance Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molitch's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 14 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile